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Abstract
Background
Serum uric acid (UA) level has been reported to be associated with chronic allograft
nephropathy and graft failure in patients who undergo kidney transplantation (KT). However,
the role of serum UA level in renal graft survival remains controversial.
Objective
This study aimed to investigate the effect of mean serum UA level during two different post-
KT periods on long-term renal graft outcomes in a large population cohort in which living
donor KT prevails.
Material and methods
A retrospective cohort study was performed using KT data prospectively collected at a sin-
gle institution. Patients (n = 2,993) were divided into low-, normal-, and high-UA groups
according to the mean serum UA level within the first year (1-YR) and 1–5 years (5-YR)
after transplantation.
Results
In the 1-YR Cox proportional hazards analysis, the low- and high-UA groups had a signifi-
cantly decreased and increased risk, respectively, for overall graft failure (OGF), death-cen-
sored graft failure (DCGF), and composite event (return to dialysis, retransplantation, death
from graft dysfunction, and 40% decline in estimated glomerular filtration rate) compared
with the normal-UA group. Similarly, in the 5-YR analysis, the low-UA group had a signifi-
cantly reduced risk of DCGF compared with the normal-UA group, whereas the high-UA
group had a significantly increased risk of all three graft outcomes. In a marginal structural
PLOS ONE | https://doi.org/10.1371/journal.pone.0209156 December 14, 2018 1 / 14
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Kim DG, Choi HY, Kim HY, Lee EJ, Huh
KH, Kim MS, et al. (2018) Association between
post-transplant serum uric acid levels and kidney
transplantation outcomes. PLoS ONE 13(12):
e0209156. https://doi.org/10.1371/journal.
pone.0209156
Editor: Kourosh Saeb Parsy, University of
Cambridge, UNITED KINGDOM
Received: June 11, 2018
Accepted: December 2, 2018
Published: December 14, 2018
Copyright: © 2018 Kim et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: The authors received no specific funding
for this work.
Competing interests: The authors have declared
that no competing interests exist.
model, hyperuricemia had a significant causal effect on worsening graft outcomes, with con-
sideration of all confounding variables (OGF: hazard ratio [HR] 2.27, 95% confidence inter-
val [CI] 1.33–3.78; DCGF: HR 2.38, 95% CI 1.09–4.9; composite event: HR 3.05, 95% CI
1.64–5.49).
Conclusions
A low-to-normal serum UA level within the first year and 1–5 years after KT is an indepen-
dent factor for better renal allograft outcomes in the long-term follow-up period rather than
high serum UA level.
Introduction
Kidney transplantation (KT) has been considered the best treatment for patients with end-
stage renal disease. However, the exact mechanisms of renal graft failure remain unclear in
pediatric and adult patients despite various studies on improvement in graft survival [1,2].
Therefore, many researchers have performed investigations to identify pathological mecha-
nisms and risk factors for renal graft failure [3].
The mean serum uric acid (UA) level during the first 6 months after transplantation has
been reported to be an independent predictor of long-term graft survival and short-term graft
function [4], and early-onset hyperuricemia at 3 months after KT showed an increased risk for
graft failure in the propensity-score matching analysis of a multicenter cohort study [5]. In
contrast, previous randomized controlled trials have reported that serum UA level is not an
independent risk factor for graft failure [5,6]. There was no association between renal function
decline at 1 or 3 years and high UA levels at 1 month after KT after correcting for baseline
renal function in a subanalysis of the Symphony study [6]. Furthermore, Kim et al. showed
that serum UA level is not an independent risk factor for graft failure after accounting for graft
function as a time-varying confounder [7].
However, numerous studies on patients with chronic kidney disease (CKD) have suggested
a link between serum UA levels and renal dysfunction [8,9]. Moreover, treatment of asymp-
tomatic hyperuricemia leads to improved patient and graft survival. Considering the link
between UA level and risk of diabetes, metabolic syndrome, hypertension, and cardiovascular
diseases, lowering the UA level to minimize these risk factors may be beneficial for graft func-
tion. Minimizing the use of diuretics and cyclosporine and avoiding purine-rich foods and
alcohol are also effective strategies to decrease the serum UA level in KT recipients [10].
The present study aimed to investigate the effect of low, normal, or high post-transplant
serum UA levels during two different post-KT periods on long-term renal graft outcomes in a
large Korean population cohort in which living donor KT prevails. We used an approach that
simultaneously accounts for time-varying exposures and confounders, allowing valid infer-
ences to be made from complex longitudinal data in observational cohort studies [7,11].
Materials and methods
Data source
A retrospective cohort study was conducted using data of 2,993 patients who underwent KT
from January 1992 to December 2014 at Severance Hospital, Yonsei University College of
Medicine. The serum UA level was measured at 1, 3, 6, 9, and 12 months after transplantation
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and then annually throughout the study period. The serum creatinine level was also measured
at the same time points, and the estimated glomerular filtration rate (eGFR) was calculated
using the Chronic Kidney Disease Epidemiology Collaboration formula [12].
Study population selection process
The study population selection process and exclusion criteria are shown in Fig 1.
Patients were divided into low-UA, normal-UA, and high-UA groups according to the
mean serum UA level within the first year (1-YR) and 1–5 years (5-YR) after KT. High serum
UA level was defined as a mean serum UA level>7.0 mg/dL in men and>6.0 mg/dL in
women. Cutoff values for the low-UA group were defined using the sex-specific 10th percentile
value from our data distribution (S1 Fig). Each group showed a similar serum UA level trajec-
tory over time in the two analyses, maintaining the original grouping (S2 Fig).
Patients with grafts and survival exceeding 1 year were included (n = 2,494) in the 1-YR
analysis, with a mean follow-up period of 130.9±74.4 months (maximum, 302 months),
Fig 1. Algorithm used to define the study cohort. Uric acid (UA) grouping was performed according to the mean serum UA level within the first year (measured at 1,
3, 6, 9, and 12 months) and 1–5 years (measured annually) after transplantation in the 1-YR and 5-YR analyses, respectively.
https://doi.org/10.1371/journal.pone.0209156.g001
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whereas patients who underwent KT from 2011 to 2014 and those with survival <5 years were
excluded in the 5-YR analysis. Thus, a total of 1,807 patients were eligible for the 5-YR analysis,
with a mean follow-up period of 160±64.6 months (maximum, 302 months).
The primary endpoints were overall graft failure (OGF), death-censored graft failure
(DCGF), and composite event, defined as the sum of return to dialysis, retransplantation,
death from graft dysfunction, and>40% decline in eGFR from the baseline level, which was
measured at 1 year (1-YR analysis) or 5 years (5-YR analysis) after transplantation. The sec-
ondary endpoint was eGFR decline.
The study was performed in accordance with the Declaration of Helsinki principles and
approved by the independent institutional review board of Yonsei University College of Medi-
cine (IRB no. 4-2017-0834). Moreover, the clinical and research activities being reported are
consistent with the Principles of the Declaration of Istanbul as outlined in the “Declaration of
Istanbul on Organ Trafficking and Transplant Tourism.”
Statistical analysis
Group differences in baseline characteristics were evaluated using Pearson’s chi-squared test
for categorical variables and one-way analysis of variance with post-hoc testing using Bonfer-
roni’s method for continuous variables. The association between serum UA level and graft out-
comes was evaluated using Kaplan–Meier survival curves and log-rank test (low- and high-UA
groups versus normal-UA group). To determine whether UA group was an independent risk
factor for the three graft outcomes, Cox proportional hazards analyses were performed with
the following models: 1) model 1 adjusted for transplant era, age, sex, body mass index, donor
type, donor age, donor sex, number of human leukocyte antigen mismatches, pre-transplant
diabetes mellitus, duration of pre-transplant dialysis, retransplantation, tacrolimus use,
delayed graft function, biopsy-proven acute rejection within 1 year, systolic/diastolic blood
pressure, and eGFR at 1 month after KT and 2) model 2 adjusted for covariates in model 1
with eGFR at 1 year after KT rather than at 1 month. The results of the Cox analysis are pre-
sented as hazard ratios (HRs) with 95% confidence intervals.
Repeated-measures variables, such as serum UA level and eGFR, were evaluated using a lin-
ear mixed model. We estimated eGFR variation based on the baseline value and evaluated
group differences in eGFR changes over time. Considering serum UA level as a time-varying
factor, time-varying Cox models were fitted with adjustment for baseline covariates to confirm
the effects of serum UA level on graft outcomes. However, this analysis could not confirm a
causal relationship between serum UA level and graft outcomes, as serum UA and eGFR affect
each other. Therefore, we used marginal structural models (MSMs) [13] to estimate the causal
effect of the time-varying serum UA level on graft outcomes in the presence of the time-vary-
ing confounder, eGFR, which is affected by the prior serum UA level. These models can be
used to create a pseudo-population by implementing inverse probability of treatment weight-
ing, which renders the relationship between serum UA level and other confounders, especially
eGFR, independent. Because small errors could result in large weights, it was difficult to esti-
mate the density of the serum UA level as a continuous or polytomous variable. Therefore,
only two UA categories (high and normal) were used in the time-varying Cox models and
MSMs. Multiple imputation using chained equations was used to handle missing data. Analy-
ses were performed on five sets of imputed data, and estimates were combined using Rubin’s
rules.
Most statistical analyses were performed using SPSS version 23.0 (IBM Corp., Armonk,
NY, USA). SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) was used for the linear mixed
model and time-varying Cox analyses, whereas R software version 3.4.3 (R Foundation for
Uric acid and long-term kidney transplantation outcomes
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Statistical Computing, Vienna, Austria) was used for the MSMs and multiple imputation. P-
values<0.05 were considered significant.
Results
Baseline characteristics
The baseline characteristics are summarized in Tables 1 and 2 for the 1-YR and 5-YR analyses,
respectively.
In the 1-YR analysis, there were significant group differences in several variables known to
affect graft outcomes, including transplant era, age, donor type, donor age, pre-transplant dia-
betes mellitus, delayed graft function, and biopsy-proven acute rejection within 1 year [14], as
well as in other baseline values, such as donor sex, duration of pre-transplant dialysis, and sys-
tolic/diastolic blood pressure at 1 month after KT. In contrast, sex, body mass index, number
of human leukocyte antigen mismatches, and tacrolimus use were similar among the groups in
the 1-YR analysis. In addition, the eGFR at 1 month after KT was significantly lower in the
high-UA group than in the normal-UA group and in the normal-UA group than in the low-
Table 1. Comparisons of baseline characteristics among UA groups according to the mean serum UA level within the first year after transplantation in the 1-YR
analysis.
UA groups for 1-YR analysis
Variables Low
(n = 252)
Normal
(n = 1566)
High
(n = 676)
P value
Transplant era <0.001
1992–2003 94 (37.3%)†‡ 751 (47.8%)�‡ 426 (62.6%)�†
2004–2014 158 (62.7%) 819 (52.2%) 254 (37.4%)
Age (years) 43.5 ± 11.3†‡ 41.3 ± 11.1�‡ 39.5 ± 10.9�† <0.001
Sex, male 158 (62.7%) 999 (63.6%) 430 (63.2%) 0.95
BMI (kg/m2) 21.7 ± 2.9 21.8 ± 3.1 22.0 ± 3.2 0.12
Donor type, deceased 15 (6.0%)†‡ 211 (13.4%)�‡ 146 (21.5%)�† <0.001
Donor age (years) 38.0 ± 10.2‡ 39.0 ± 11.9 40.1 ± 12.5� 0.02
Donor sex, male 108(42.9%)†‡ 870 (55.4%)� 400 (58.8%)� <0.001
Pretransplant DM 47 (18.7%)†‡ 169 (10.8%)�‡ 23 (3.4%)�† <0.001
Duration of pretransplant dialysis
(months)
15.4 ± 29.4†‡ 26.4 ± 40.2�‡ 36.3 ± 46.2�† <0.001
Retransplantation 14 (5.6%) 143 (9.1%) 64 (9.4%) 0.15
Number of HLA mismatches 2.5 ± 1.3 2.5 ± 1.2 2.4 ± 1.2 0.60
Tacrolimus use 101 (40.1%)† 624 (39.7%)� 236 (34.7%) 0.07
Delayed graft function 1 (0.4%)†‡ 49 (3.1%)�‡ 53 (7.8%)�† <0.001
BPAR within 1 year 17 (6.7%)†‡ 295 (18.8%)�‡ 225 (33.1%)�† <0.001
SBP at 1 month (mmHg) 129.3 ± 13.7‡ 129.9 ± 14.4‡ 132.8 ±14.6�† <0.001
DBP at 1 month (mmHg) 83.0 ± 10.2‡ 83.2 ± 10.3‡ 85.0 ± 10.9�† 0.001
eGFR at 1 month (mL/min) 72.9 ± 17.9†‡ 65.6 ± 19.7�‡ 56.2 ± 20.9�† <0.001
eGFR at 1 year (mL/min) 73.7 ± 16.0†‡ 67.8 ± 16.9�‡ 58.6 ± 17.4�† <0.001
Mean serum UA within 1st year (mg/dL) 3.69 ± 0.52†‡ 5.47 ± 0.78�‡ 7.68 ± 1.15�† <0.001
�P<0.05 versus the low-UA group
†P<0.05 versus the normal-UA group
‡P<0.05 versus the high-UA group in the post-hoc analysis
UA, uric acid; BMI, body mass index; DM, diabetes mellitus; HLA, human leukocyte antigen; BPAR, biopsy-proven acute rejection; SBP, systolic blood pressure; DBP,
diastolic blood pressure; eGFR, estimated glomerular filtration rate
https://doi.org/10.1371/journal.pone.0209156.t001
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UA group. Similar group differences in variables except for sex, donor sex, retransplantation,
and tacrolimus use were observed in the 5-YR analysis.
Graft outcomes
In the 1-YR analysis, there were significant group differences in the Kaplan–Meier survival
curves for overall graft survival, death-censored graft survival, and composite event-free sur-
vival. The low- and high-UA groups had significantly better and worse outcomes, respectively,
than the normal-UA group. Similar results were obtained in the 5-YR analysis, with signifi-
cantly worse outcomes in the high-UA group than in the normal-UA group; however, only
death-censored graft survival was significantly higher in the low-UA group than in the nor-
mal-UA group (Fig 2).
Cox proportional hazards analyses were performed to confirm that serum UA level was an
independent factor affecting graft outcomes (Fig 3).
In the 1-YR analysis, the low-UA group had a lower risk of OGF, DCGF, and composite
event than the normal-UA group when fitted with model 1. In model 2, the low-UA group still
Table 2. Comparisons of baseline characteristics among UA groups according to the mean serum UA level within 1–5 years after transplantation in the 5-YR
analysis.
UA groups for 5-YR analysis
Variables Low
(n = 184)
Normal
(n = 930)
High
(n = 693)
P value
Transplant era <0.001
1992–2000 71 (38.6%) 426 (45.8%) 410 (59.2%)
2001–2010 113 (61.4%) 504 (54.2%) 283 (40.8%)
Age (years) 43.9 ± 10.5†‡ 40.6 ± 10.5�‡ 37.7 ± 10.5�† <0.001
Sex, male 117 (63.6%) 556 (59.8%) 484 (69.8%) <0.001
BMI (kg/m2) 21.8 ± 3.0 21.6 ± 3.1 21.6 ± 2.9 0.72
Donor type, deceased 4 (2.2%) 66 (7.1%) 77 (11.1%) <0.001
Donor age (years) 36.3 ± 10.0‡ 37.7 ± 11.0‡ 39.1 ± 12.2�† 0.005
Donor sex, male 98 (53.3%) 553 (57.3%) 388 (56.0%) 0.58
Pretransplant DM 30 (16.3%) 88 (9.5%) 19 (2.7%) <0.001
Duration of pretransplant dialysis
(months)
14.6 ± 25.0†‡ 22.2 ± 35.3� 26.0 ± 39.7� 0.001
Retransplantation 10 (5.4%) 79 (8.5%) 77 (11.1%) 0.04
Number of HLA mismatches 2.4 ± 1.1 2.4 ± 1.1 2.4 ± 1.2 0.98
Tacrolimus use 71 (38.6%) 290 (31.2%) 161 (23.2%) <0.001
Delayed graft function 0 (0%)‡ 20 (2.0%) 21 (3.0%)� 0.03
BPAR within 1 year 27 (14.7%) 198 (21.3%) 227 (32.8%) <0.001
SBP at 1 month (mmHg) 130.0 ± 14.7 130.0 ± 14.3‡ 133.3 ± 14.4† <0.001
DBP at 1 month (mmHg) 83.7 ± 10.6 83.5 ± 10.2‡ 85.4 ± 10.3† 0.001
eGFR at 1 month (mL/min) 70.6 ± 18.7†‡ 65.6 ± 19.7�‡ 60.6 ± 20.3�† <0.001
eGFR at 1 year (mL/min) 74.7 ± 17.1†‡ 68.9 ± 16.0�‡ 60.6 ± 16.0�† <0.001
Mean serum UA between 1 and 5 year (mg/dL) 3.86 ± 0.62†‡ 5.62 ± 0.77�‡ 7.83 ± 1.11�† <0.001
�P<0.05 versus the low-UA group
†P<0.05 versus the normal-UA group
‡P<0.05 versus the high-UA group in the post-hoc analysis
UA, uric acid; BMI, body mass index; DM, diabetes mellitus; HLA, human leukocyte antigen; BPAR, biopsy-proven acute rejection; SBP, systolic blood pressure; DBP,
diastolic blood pressure; eGFR, estimated glomerular filtration rate
https://doi.org/10.1371/journal.pone.0209156.t002
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had a lower risk of DCGF and composite event than the normal-UA group. The high-UA
group had significantly higher HRs for all three graft outcomes than the normal-UA group in
models 1 and 2.
In the 5-YR analysis, the low-UA group had a significantly lower risk of DCGF than the
normal-UA group in models 1 and 2. The risk of OGF and composite event did not signifi-
cantly differ between the low- and normal-UA groups. The high-UA group had significantly
higher HRs for all three graft outcomes than the normal-UA group in models 1 and 2. The
complete results of the multivariate analyses are provided in S1–S3 Tables.
eGFR decline
To evaluate the association between UA level and progression of graft dysfunction, eGFR
decline was compared among the three groups (Fig 4).
Because the baseline eGFR was significantly different among groups, we used a linear
mixed model to compare the least-squares (LS) mean eGFR and cumulative eGFR decline at
each time point, adjusting for all confounding variables. In the 1-YR analysis, the LS mean
eGFR was significantly higher in the low-UA group than in the normal-UA group, especially
during the first decade. In addition, the LS mean eGFR was significantly lower in the high-UA
group than in the normal-UA group, especially during later periods. Changes in the LS mean
eGFR over time were not significantly different among the three groups (P = 0.07). However,
Fig 2. Kaplan–Meier estimates for overall graft survival, death-censored graft survival, and composite event-free survival. (a), (b), and (c) show comparisons of
survival according to the mean serum uric acid (UA) level within the first year after transplantation (1-YR analysis); (d), (e), and (f) show comparisons of survival
according to the mean serum UA level within 1–5 years after transplantation (5-YR analysis). The composite event represents the sum of return to dialysis,
retransplantation, death from graft dysfunction, and eGFR decline of more than 40% from the baseline level, which was measured at 1 year or 5 years after
transplantation (for the 1-YR and 5-YR analyses, respectively). The log-rank P-values for the low- and high-UA groups were estimated using the normal-UA group as
reference. eGFR, estimated glomerular filtration rate.
https://doi.org/10.1371/journal.pone.0209156.g002
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the cumulative eGFR decline was significantly lower and higher in the low-and high-UA
groups, respectively, than in the normal-UA group, mainly during later periods, with a signifi-
cant group-by-time interaction effect (P = 0.01).
In the 5-YR analysis, the LS mean eGFR and cumulative eGFR decline were significantly
lower and higher, respectively, in the high-UA group than in the normal-UA group through-
out the follow-up period, whereas these measures were not significantly different between the
low- and normal-UA groups. The group-by-time interactions were not significant in the 5-YR
analysis (LS mean eGFR: P = 0.79; cumulative eGFR decline: P = 0.78). The results of compari-
sons at each time point are presented in S2 Table.
Time-varying hyperuricemia and graft outcomes in the presence of time-
varying eGFR
Hyperuricemia was significantly associated with an increased risk of all three graft outcomes
in the time-varying Cox analysis, adjusting for the same covariates as those used in the conven-
tional Cox model, plus the time-varying UA level. Furthermore, significance remained for all
outcomes after imputation of missing serum UA level and eGFR values. In the MSMs, hyper-
uricemia still had a significant causal effect on worsening graft outcomes (OGF, DCGF, and
composite event), with consideration of all confounding variables (Table 3).
Discussion
Average low-to-normal serum UA levels within the first year and 1–5 years after KT had a pos-
itive effect on long-term graft outcomes in KT recipients in this study. In particular, low serum
UA levels after KT were associated with significantly better graft outcomes than normal serum
UA levels. Consistent with previous reports, the present study also showed that hyperuricemia
Fig 3. Forest plots of the Cox proportional hazards models for graft outcomes. Adjusted hazard ratio estimates and 95% confidence intervals for overall graft
failure (OGF), death-censored graft failure (DCGF), and composite event are displayed according to the mean serum uric acid (UA) level within the first year (a) and
1–5 years (b) after transplantation. Covariates used in model 1 were as follows: transplant era, age, sex, body mass index, donor type, donor age, donor sex, pre-
transplant diabetes mellitus, duration of pre-transplant dialysis, retransplantation, number of human leukocyte antigen mismatches, tacrolimus use, delayed graft
function, biopsy-proven acute rejection within 1 year, systolic/diastolic blood pressure at 1 month, and eGFR at 1 month after kidney transplantation. Covariates used
in model 2 included those used in model 1, with eGFR at 1 year after kidney transplantation rather than at 1 month. The composite event represents the sum of return
to dialysis, retransplantation, death from graft dysfunction, and eGFR decline of more than 40% from the baseline level, which was measured at 1 year or 5 years after
transplantation (for the 1-YR and 5-YR analyses, respectively). HR, hazard ratio; CI, confidence interval; eGFR, estimated glomerular filtration rate.
https://doi.org/10.1371/journal.pone.0209156.g003
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was associated with an increased risk of long-term graft failure compared with normal serum
UA levels [15]. The mean follow-up period was over 160 months, which allowed the classifica-
tion of mean serum UA levels over 1–5 years and over the first year. In addition, we estimated
the causal relationship between high serum UA levels and graft outcomes using MSMs, as in
previous similar studies [5,7].
Various time points have been used to investigate the causal relationship between serum
UA level and graft outcomes (e.g., 1, 3, 6, and 12 months after KT) [4,6,15–20]. Previous ran-
domized controlled trials that failed to indicate an association between mean UA levels and
graft outcomes such as the Symphony study used limited time points [6]. In contrast, in the
present study, serum UA levels were averaged over two different periods (within the first year
and 1–5 years after KT). To our knowledge, the present study is the first to investigate whether
low-to-normal serum UA levels averaged over different periods after KT are associated with
better long-term graft survival in KT recipients. Although some results were similar for both
analyses, some differences were observed. For example, in the 1-YR analysis, the low-UA
group had a lower risk of all three graft outcomes than the normal-UA group, whereas in the
5-YR analysis, the low-UA group had a significantly lower risk of only DCGF than the nor-
mal-UA group. In addition, in the 1-YR analysis, the low-UA group had significantly lower LS
mean eGFR and cumulative eGFR decline than the normal-UA group during the follow-up
period. However, in the 5-YR analysis, the low- and normal-UA groups did not significantly
differ with respect to both eGFR variables. In addition, the high-UA group had significantly
Fig 4. Comparisons of eGFR decline using linear mixed models. Differences in eGFR decline from the baseline level (eGFR at 1 year after transplantation)
according to the mean serum uric acid (UA) level within the first year after transplantation (1-YR analysis) are shown in (a) and (b). Differences in eGFR decline
from the baseline level (eGFR at 5 years after transplantation) according to the mean serum UA level within 1–5 years after transplantation (5-YR analysis) are
shown in (c) and (d). The eGFR and eGFR decline are presented as least-squares means, adjusting for all covariates (including the baseline eGFR) using linear mixed
models. P-values for the group-by-time interaction effect were calculated. �: P<0.05, low-UA group versus normal-UA group, †: P<0.05, high-UA group versus
normal-UA group. eGFR, estimated glomerular filtration rate.
https://doi.org/10.1371/journal.pone.0209156.g004
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increased HRs for OGF, DCGF, and composite event within the first year and 1–5 years after
KT. Unlike those of previous studies, our results suggest that serum UA levels during different
periods after KT have different associations with renal allograft outcomes [5,7,15,21,22].
The association between each cutoff value for post-transplant serum UA levels and KT out-
comes has not been fully established. Higher UA levels were associated with a greater eGFR
decline than a UA level of<6 mg/dL in an increasing dose–response relationship [23]. Fur-
thermore, in patients with mild-to-severe CKD, higher serum UA level was independently
associated with the risk of renal failure, although with a J-shaped relationship between UA
level and all-cause mortality [24]. Low and high serum UA levels may show a similar associa-
tion with unfavorable renal function outcomes, as low serum UA level can result from poor
protein intake, decreased daily intake of purines or nucleotides, and malnutrition, which are
associated with poor outcomes in CKD [25–27]. However, as of yet, there is no commonly
accepted lower limit for the serum UA level in KT recipients. Therefore, we defined the low-
UA group using the sex-specific 10th percentile value (<4.5 mg/dL and<3.8 mg/dL in male
and female recipients, respectively). Furthermore, high serum UA level was defined in the
present study as a mean serum UA level>7.0 mg/dL in men and>6.0 mg/dL in women, con-
sistent with previous epidemiologic studies [7,28].
In this Korean cohort, only 14.9% of patients received deceased donor KT (all from brain
death). We could not confirm the superiority of low UA level in deceased donor KT owing to
the scarcity of patients with low UA level. However, high UA level was still significantly associ-
ated with worse outcomes in these patients. Further studies investigating the benefit of main-
taining low UA level during the early post-transplant period in deceased donor KT patients
would be required.
Table 3. Association between time-varying hyperuricemia and graft outcomes.
Models HR (95% CI) P value
Time varying Cox without imputationa
OGF 2.07(1.70–2.52) <0.001
DCGF 2.08 (1.61–2.69) <0.001
Composite event 2.73 (2.32–3.21) <0.001
Time varying Cox with imputationb
OGF 1.96 (1.59–2.43) <0.001
DCGF 2.02 (1.55–2.63) <0.001
Composite event 3.15 (2.6–3.81) <0.001
Marginal structural modelc
OGF 2.27(1.33–3.78) 0.002
DCGF 2.38 (1.09–4.90) 0.03
Composite event 3.05 (1.64–5.49) 0.004
UA level (high or normal) was considered a time-varying dichotomous variable
aAdjusted for transplant era, age, sex, body mass index, donor type, donor age, donor sex, pre-transplant diabetes
mellitus, duration of pre-transplant dialysis, retransplantation, number of human leukocyte antigen mismatches,
tacrolimus use, delayed graft function, biopsy-proven acute rejection within 1 year, baseline systolic/diastolic blood
pressure, and time-varying eGFR
bMultiple imputation using chained equations for the missing UA level and eGFR values
cPerformed using the imputed dataset and the model created with consideration of all confounders, including time-
varying eGFR
OGF, overall graft failure; DCGF, death-censored graft failure; HR, hazard ratio; CI, confidence interval; eGFR,
estimated glomerular filtration rate; UA, uric acid
https://doi.org/10.1371/journal.pone.0209156.t003
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Post-transplant hyperuricemia is associated with the use of immunosuppressive regimens that
include cyclosporine, decreased glomerular filtration rate, diuretic use, and obesity during differ-
ent follow-up periods [15,29–32]. An elevated serum UA level is thought to be a prognostic
marker for disease progression in patients with CKD and plays an important role in the develop-
ment of renal insufficiency in individuals with normal renal function [15,33–35]. Furthermore,
renal injuries occur in experimental models of hyperuricemia, which can be prevented if the
serum UA level is maintained within the normal range using UA-lowering agents [15,36–38].
Several mechanisms for the effect of UA on renal graft failure have been proposed. Hyper-
uricemia may be a consequence of reduced glomerular filtration rate in the renal allograft and
might contribute to glomerular hypertrophy and tubulointerstitial fibrosis itself [15,36,37]. In
addition, the serum UA level is associated with changes in renal plasma flow, arterial stiffness,
and endothelial dysfunction via impairment of nitric oxide generation in vascular endothelial
cells [39–41]. Furthermore, these factors can result in chronic allograft nephropathy, which is
a major cause of late graft loss [42–44]. Hyperuricemia might be associated with diabetes, met-
abolic syndrome, hypertension, and cardiovascular diseases in KT recipients who are at risk of
these conditions. The present study similarly showed that hyperuricemia was associated with
an increased risk of worse renal graft outcomes in a time-varying Cox model, with consider-
ation of the confounding effect of time-varying eGFR. In contrast to a previous report [7],
hyperuricemia still had a causal effect on renal graft outcomes in the MSMs, with consider-
ation of all confounding variables in our dataset.
The present study has several limitations. First, the study used a retrospective cohort design.
Second, an extremely low serum UA level could be due to comorbid conditions common in
KT recipients [45]. Third, we could not exclude the possibility that our findings were affected
by dietary intake. Certain dietary habits [46], meat or seafood intake, and alcohol consumption
are associated with a higher prevalence of hyperuricemia [47]. Finally, the eGFR was calculated
using serum creatinine, which is dependent on muscle mass, and the generation and tubular
secretion of creatinine [48,49]. Low serum creatinine levels can result from muscle wasting
due to comorbid conditions in KT recipients [45].
In conclusion, a low-to-normal serum UA level within the first year and 1–5 years after KT
might be an independent factor for better renal allograft outcomes in the long-term follow-up
period. In addition, the present study more clearly clarifies the association between serum UA
levels and KT outcomes, adjusting for time-varying confounding variables. Despite the use of
diverse research designs, patient populations, and statistical methods, the effect of serum UA
levels on KT outcomes remains unclear. Further experimental and clinical evidence is required
to determine whether serum UA level is an independent therapeutic target for KT outcomes.
Supporting information
S1 Fig. Distribution of mean serum uric acid (UA). The distribution of mean UA within the
first year after transplantation is shown in (a) and (b), whereas (c) and (d) show the mean UA
from 1 to 5 years after transplantation in men and women, respectively.
(TIF)
S2 Fig. Uric acid (UA) changes over time. The changes in the serum UA level over time
according to the mean serum UA level within the first year after transplantation are shown in
(a) and (b). The changes in the serum UA level over time according to the mean serum UA
level from 1 to 5 years after transplantation are shown in (c) and (d). �: P-values of the group-
by-time effect between the low- and normal-UA groups; ��: P-values of the group-by-time
effect between the high- and normal-UA groups.
(TIF)
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S1 Table. Multivariate Cox proportional hazard analysis for overall graft survival.
(DOCX)
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